WS Investor
25 Aug 2026, 17:02
Moderna Stock Surges 14% After Wolfe Research Upgrade
Moderna (NASDAQ: MRNA) shares surged about 14.1% on Tuesday after Wolfe Research upgraded the biotechnology company to Peer Perform from Underperform, improving Wall Street sentiment toward the stock.
Analyst Alexandria Hammond's upgrade removes Wolfe Research's bearish rating on Moderna and signals a more balanced assessment of the company's risk-reward profile.
Why Is Moderna Stock Rising?
The upgrade appears to be an important catalyst for Tuesday's sharp move. A shift from Underperform to Peer Perform suggests Wolfe Research no longer expects Moderna to materially lag comparable biotechnology stocks.
Investor attention is also increasingly focused on Moderna's pipeline beyond COVID-19 vaccines, particularly its cancer vaccine program. The company is developing an individualized neoantigen therapy, intismeran autogene (mRNA-4157/V940), with Merck's Keytruda. The program represents one of Moderna's most important opportunities to demonstrate that its mRNA technology can expand successfully into oncology.
Positive progress in cancer vaccines could significantly broaden Moderna's long-term growth profile beyond respiratory vaccines and remains an important component of the investment case surrounding the company.
## Sentiment Improves, but Rating Remains Cautious
The Peer Perform rating is not equivalent to a Buy or Outperform recommendation. Instead, it indicates that Wolfe Research has become less bearish on Moderna.
Still, the 14% rally suggests investors are responding strongly to the removal of the Underperform rating, while Moderna's cancer vaccine opportunity and broader mRNA pipeline continue to provide potentially significant long-term catalysts.
Moderna (NASDAQ: MRNA) shares surged about 14.1% on Tuesday after Wolfe Research upgraded the biotechnology company to Peer Perform from Underperform, improving Wall Street sentiment toward the stock.
Analyst Alexandria Hammond's upgrade removes Wolfe Research's bearish rating on Moderna and signals a more balanced assessment of the company's risk-reward profile.
Why Is Moderna Stock Rising?
The upgrade appears to be an important catalyst for Tuesday's sharp move. A shift from Underperform to Peer Perform suggests Wolfe Research no longer expects Moderna to materially lag comparable biotechnology stocks.
Investor attention is also increasingly focused on Moderna's pipeline beyond COVID-19 vaccines, particularly its cancer vaccine program. The company is developing an individualized neoantigen therapy, intismeran autogene (mRNA-4157/V940), with Merck's Keytruda. The program represents one of Moderna's most important opportunities to demonstrate that its mRNA technology can expand successfully into oncology.
Positive progress in cancer vaccines could significantly broaden Moderna's long-term growth profile beyond respiratory vaccines and remains an important component of the investment case surrounding the company.
## Sentiment Improves, but Rating Remains Cautious
The Peer Perform rating is not equivalent to a Buy or Outperform recommendation. Instead, it indicates that Wolfe Research has become less bearish on Moderna.
Still, the 14% rally suggests investors are responding strongly to the removal of the Underperform rating, while Moderna's cancer vaccine opportunity and broader mRNA pipeline continue to provide potentially significant long-term catalysts.
